Conditions which augment systemic absorption include the application of the more potent steroids, use over large surface areas, prolonged use, and the addition of occlusive dressings. Therefore, patients receiving a large dose of a potent topical steroid applied to a large surface area or under an occlusive dressing should be evaluated periodically for evidence of HPA axis suppression by using the urinary free cortisol and ACTH stimulation tests. If HPA axis suppression is noted, an attempt should be made to withdraw the drug, to reduce the frequency of application, or to substitute a less potent steroid.
The Oxandrolone hormone does not carry any estrogenic related side effects. It does not aromatize and cannot lead to gynecomastia or water retention due to increases in estrogen levels. It further carries no progestin related activity, which again supports no estrogenic related side effects. Due to water retention being impossible with this steroid, this will decrease the risk of high blood pressure. Excess water retention can promote high blood pressure. Some steroids that do not aromatize can lead to high blood pressure, such as Trenbolone , but Anavar is rarely associated with this trait.
Cystic fibrosis is a rare disease that affects about 30,000 people in the United is indicated for patients aged 2 and older who have one mutation in the CFTR gene that is responsive to drug treatment based on clinical and/or in vitro (laboratory) data. The expanded indication will affect another 3 percent of the cystic fibrosis population, impacting approximately 900 patients. Kalydeco serves as an example of how successful patient-focused drug development can provide greater understanding about a disease. For example, the Cystic Fibrosis Foundation maintains a 28,000-patient registry, including genetic data, which it makes available for research.